Ottawa, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The global hyperlipidemia drugs market size was valued at USD 23.8 billion in 2024 and is predicted to hit around USD 30.62 billion by 2033, a study ...

Other factors that may complicate treatment of hyperlipidemia include metabolism of many antiretroviral drugs by the cytochrome P-450 isoenzyme system, polypharmacy, and drug-food interactions.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

This page is a valuable resource, featuring a complete guide to the latest medications-both generic and branded-ideal for relieving High Cholesterol symptom. Learn about various drugs, from their ...

Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD) among all racial/ethnic groups. However, there are certain racial/ethnic differences in the ...

The sales growth was driven by independently developed improved and combination drugs such as the hyperlipidemia combination drug "Rosuzet" and the antihypertensive combination product line ...

(MENAFN- GlobeNewsWire - Nasdaq) The global hyperlipidemia drugs market size is calculated at USD 24.47 billion in 2025 and is expected to reach around USD 31.49 billion by 2034, growing at a CAGR ...